Isth0036
Witryna30 lis 2024 · ISTH0036 could be the first drug that targets and prevents development of fibrosis and therefore may become a unique and promising new therapy for retinal indications,” said Dr. René Rückert ... Witryna11 maj 2015 · ISTH0036 is a locked nucleic acid-modified antisense oligonucleotide, currently in phase I development for the treatment of advanced-stage glaucoma. As described in the podium presentation, ISTH0036 was administered to evaluate its therapeutic potential in murine models of glaucoma filtration surgery (GFS) and laser …
Isth0036
Did you know?
Witryna10 cze 2015 · About ISTH0036 ISTH0036 is a locked nucleic acid-modified antisense oligonucleotide selectively targeting the messenger ribonucleic acid (mRNA) of TGF … WitrynaSTUDY OVERVIEW: Phase IIa, multicenter study to evaluate ISTH0036, an antisense targeting mRNA of TGF-β and protein downregulation in DME and nAMD. Plan to enroll up to 50 patients. SPONSOR: Isarna Therapeutics GmbH STUDY OBJECTIVE: Evaluate the influence of automated OCT image enrichment (using AI) on disease …
WitrynaIn vivo, ISTH0036 was administered via intravitreal (IVT) injection to eyes of several preclinical species. Ocular tissues were analyzed for tissue drug concentrations and … WitrynaIsarna Therapeutics GmbH 279 obserwujących na LinkedIn. Developing first in class antisense therapies for blockbuster retina indications. Isarna Therapeutics is a clinical stage biotech company, headquartered in Munich, Germany. Isarna develops ISTH0036, a next-generation antisense to block TGF-beta 2 production, a key molecule in the …
WitrynaIn this article, Drs. Idowu and Bourne discuss a stepwise approach to the surgical management of traumatic glaucoma. In addition to reviewing traditional glaucoma surgeries, they explore the role of microinvasive glaucoma surgery (MIGS) in traumatic glaucoma. —Sarwat Salim, MD, section editor. Glaucoma secondary to trauma can be ... Witryna30 lis 2024 · Europe PMC is an archive of life sciences journal literature. Methods. In this prospective phase I trial glaucoma patients scheduled for TE with mitomycin C (MMC) received a single intravitreal injection of ISTH0036 at the end of surgery in escalating total doses of 6.75 μg, 22.5 μg, 67.5 μg or 225 μg, resulting in calculated intraocular …
Witryna31 sie 2024 · The study’s objective is to evaluate ISTH0036 in these two indications and gain data that will enable the transition into a phase2b/3 clinical trial. The phase 2 trial …
WitrynaPreclinical and clinical data of ISTH0036, an antisense designed to suppress TGF-β2 will be presented. Purpose (100 words max) Transforming Growth Factor beta 2 (TGF … marco bertoneWitrynaISTH0036 may offer a true alternative to current standard of care treatments for two blockbuster indications. The global retinal disorder treatment market size was valued … marco bertoni university of padovaWitryna30 lis 2024 · Regarding IOP control, single-dose ISTH0036 administration of 67.5 μg or 225 μg at the time of TE resulted in IOP values persistently < 10 mmHg over the three month postoperative … marco bertorello/afp via getty imagesWitryna30 lis 2024 · PurposeTo evaluate the safety and tolerability of intravitreal ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in patients with primary open angle glaucoma (POAG) undergoing trabeculectomy (TE; glaucoma filtration surgery).MethodsIn this prospective phase I trial glaucoma … csp in digital signatureWitryna15 gru 2016 · ISTH0036 is a 14-mer phosphorothioate Locked Nucleic Acid- (LNA) modified antisense oligonucleotide gapmer, targeting the sequence of TGF-β2 mRNA and was developed for therapeutic intervention in ocular diseases. It was shown to effectively and potently downregulate target mRNA in a dose-dependent manner in … marco bertozzi linkedinWitrynaIn vivo, ISTH0036 was administered via intravitreal (IVT) injection to eyes of several preclinical species. Ocular tissues were analyzed for tissue drug concentrations and target mRNA downregulation. The toxicity of ISTH0036 was tested in the rabbit following three IVT administrations at 2-week intervals. marco bertoncelliWitryna15 maj 2024 · ISTH0036 is an antisense oligonucleotide targeting the mRNA of TGF-β2, thereby inhibiting its transcription. The new Phase I study revealed that the gene … csp industria e comercio